Nothing Special   »   [go: up one dir, main page]

MX2013013023A - Analisis y metodo para la identificacion de la capacidad de respuestas individual a tratamiento con inmunoglobulina. - Google Patents

Analisis y metodo para la identificacion de la capacidad de respuestas individual a tratamiento con inmunoglobulina.

Info

Publication number
MX2013013023A
MX2013013023A MX2013013023A MX2013013023A MX2013013023A MX 2013013023 A MX2013013023 A MX 2013013023A MX 2013013023 A MX2013013023 A MX 2013013023A MX 2013013023 A MX2013013023 A MX 2013013023A MX 2013013023 A MX2013013023 A MX 2013013023A
Authority
MX
Mexico
Prior art keywords
individual
immunoglobulin
assay
identification
awarding
Prior art date
Application number
MX2013013023A
Other languages
English (en)
Inventor
Stefan Meuer
Thomas Giese
Christian Jacobi
Stefan Haag
Juergen Roemisch
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of MX2013013023A publication Critical patent/MX2013013023A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se describe un método para determinar la probabilidad de respuesta de un individuo que padece de una enfermedad hacia el tratamiento con inmunoglobulina que comprende las etapas de proporcionar una muestra que contiene linfocitos B y T, células citolíticas naturales, células T invariables y monocitos del individuo; determinar el genotipo de por lo menos uno de los polinucleótidos de ADAMTS9-intrón, un KLHDC8A-intrón o de una región flanqueante del gen CD14 y premiar con el valor de 1 para las combinaciones de polimorfismo de nucleótido único homocigótico, lo que sugiere que la muestra de sangre proviene de una persona a la cual no responderá al tratamiento con inmunoglobulina, mientras que se premia con el valor de 0 para SNP que no satisfaga los criterios, lo que sugiere que la muestra de sangre proviene de una persona a la cual responderá al tratamiento con inmunoglobulina.
MX2013013023A 2011-06-07 2012-06-06 Analisis y metodo para la identificacion de la capacidad de respuestas individual a tratamiento con inmunoglobulina. MX2013013023A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2011059405 2011-06-07
PCT/EP2012/060699 WO2012168300A1 (en) 2011-06-07 2012-06-06 Assay and method for the identification of individual responsiveness to immunoglobulin therapy

Publications (1)

Publication Number Publication Date
MX2013013023A true MX2013013023A (es) 2013-12-02

Family

ID=46210267

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013023A MX2013013023A (es) 2011-06-07 2012-06-06 Analisis y metodo para la identificacion de la capacidad de respuestas individual a tratamiento con inmunoglobulina.

Country Status (8)

Country Link
US (1) US20150211064A1 (es)
EP (1) EP2718461A1 (es)
CN (1) CN103597096A (es)
AU (1) AU2012266409A1 (es)
BR (1) BR112013031298A2 (es)
MX (1) MX2013013023A (es)
RU (1) RU2013149574A (es)
WO (1) WO2012168300A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017138974A (ru) * 2015-04-17 2019-05-13 Игнова Гмбх Прогностические биомаркеры клинического ответа на лечение анти-лпс иммуноглобулином
CN111316098B (zh) * 2017-09-15 2024-05-14 拜克门寇尔特公司 用于治疗的基于流动的测定

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113815A2 (en) * 2004-04-26 2005-12-01 Uab Research Foundation Polymorphisms in the fcgr2b promoter and uses thereof
EP2243028A1 (en) * 2008-01-09 2010-10-27 Octapharma AG Assay and method for the assessment of responders and non-responders to nk cell modulation by immunoglobulin therapy

Also Published As

Publication number Publication date
CN103597096A (zh) 2014-02-19
WO2012168300A1 (en) 2012-12-13
BR112013031298A2 (pt) 2016-11-22
AU2012266409A1 (en) 2013-11-07
EP2718461A1 (en) 2014-04-16
US20150211064A1 (en) 2015-07-30
RU2013149574A (ru) 2015-07-20

Similar Documents

Publication Publication Date Title
WO2015135035A3 (en) Determining cancer agressiveness, prognosis and responsiveness to treatment
SG10201906673WA (en) Artificial nucleic acid molecules
WO2010062960A3 (en) METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
SG170819A1 (en) Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
WO2013056087A3 (en) Compositions and methods for treating and preventing coronary heart disease
EA201270574A1 (ru) Способы и системы для фармакогеномного лечения сердечно-сосудистых заболеваний
WO2009059321A3 (en) Rca locus analysis to assess susceptibility to amd and mpgnii
WO2007038670A3 (en) Methods and compositions for screening and treatment of disorders of blood glucose regulation
WO2008088854A3 (en) Genetic markers for predicting responsiveness to combination therapy
GB201313219D0 (en) Product selection using genetic analysis
MX350967B (es) Marcadores geneticos para myb28.
WO2008089465A3 (en) Gene polymorphisms as sex-specific predictors in cancer therapy
WO2011106549A3 (en) Methods for determining gene-nutrient interactions
PL1673473T3 (pl) Zastosowanie polimorfizmów genetycznych związanych ze skutecznością leczenia chorób zapalnych
WO2012041332A3 (en) Genetic variations in the interleukin-6 receptor gene as predictors of the response to treatment
WO2007022374A3 (en) Assessing response to anti-cd20 therapy by genotyping c1q components
WO2007095580A3 (en) Treatment response in generalized social phobia
MX2013013023A (es) Analisis y metodo para la identificacion de la capacidad de respuestas individual a tratamiento con inmunoglobulina.
MX2016012718A (es) Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina.
WO2008088876A3 (en) Tissue factor promoter polymorphisms
WO2008045344A3 (en) Methods to determine responsiveness to cisplatin treatment
Galaktionova et al. The association of polymorphisms in SLC18A1, TPH1 and RELN genes with risk of paranoid schizophrenia
ITMI20120865A1 (it) Biomarcatori per patologie del sistema nervoso centrale
EP2150627A4 (en) POLYMORPHISM IN THE APO (A) GENE PREDICTING SENSITIVITY TO ACETYLSALICYLIC ACID TREATMENT
NZ576349A (en) Equine performance test

Legal Events

Date Code Title Description
FA Abandonment or withdrawal